Shield Therapeutics plc announced that Mr. Andy Hurley will be joining Shield's Executive Team as Chief Commercial Officer, effective from the 10 April 2023. Andy brings to Shield three decades of experience as a strategic commercial leader at both large and small biopharmaceutical companies. Andy will oversee Shield's commercial organization with responsibility for US sales, marketing, operations, managed markets and patient services.

Andy Hurley joins Shield from Agenus Inc, where he was Chief Commercial and Medical/Clinical Officer. At Agenus he was responsible for leading the commercial, medical affairs and clinical operations functions and was leading the company as it prepared for multiple immuno-oncology product launches. Prior to Agenus, Andy was Senior Vice President of a commercial division at Syneos Health where he led a global team that launched nine products across several therapeutic areas during his tenure at the company.

Before that, he was Chief Commercial Officer at Ocular Therapeutix where he helped the organisation in preparing the company for its first pharmaceutical launch. Andy has also held senior leadership roles across marketing, sales, and operations functions at Sunovion, Dyax, NitroMed and Forest Pharmaceuticals. Andy has a Bachelor of Science in Consumer Studies from the University of Vermont and did post-graduate work in Finance and Marketing at Bentley University's McCallum Graduate School of Business.